Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Zap away heartburn? new device aims to tame GERD without drugs

NCT ID NCT06613438

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a device called eGERD that sends mild electrical pulses to the belly to reduce acid reflux and symptoms like heartburn. 84 adults with GERD will use either the real device or a sham version at home for several weeks. Researchers will measure acid levels in the throat and track symptom changes to see if the device is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
eGERD device (non-invasive electrical stimulation device)
What this could lead to
If it works, this could offer a drug-free, at-home option to ease heartburn and regurgitation for people with GERD.
What could go wrong
This is an early-stage trial with only 84 people, and the sham comparison means the real effect may be small. The device may not work for everyone or could cause skin irritation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 84 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female, aged 22 - 75 2. Has been typically suffering from at least three heartburn and/or regurgitation episodes per week during the past three months. 3. Undergone a wireless (Bravo) pH monitoring test during the past 24 months prior to enrollment into the current study, following a 7-day (min.) off-PPI period, with AET ≥6% (as defined in section 7.2) in at least 2 monitoring days AND when averaged over all monitoring days of the test; or, in the absence of such testing, has been determined by the Principal Investigator (PI), based on a detailed anamnesis and with written agreement from the Medical Director, to have gastroesophageal reflux disease (GERD) other than functional GERD; or Undergone a catheter-based pH monitoring test during the past 24 months prior to enrollment into the current study, following a 7-day (min.) off-PPI period, with AET ≥6% (as defined in section 7.2); or, in the absence of such testing, has been determined by the Principal Investigator (PI), based on a detailed anamnesis and with written agreement from the Medical Director, to have gastroesophageal reflux disease (GERD) other than functional GERD. 4. Able and willing to give informed consent for participation in the study and to comply with all study requirements, including operating the smartphone application. 5. Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study. Exclusion Criteria: 1. Previously undergoing gastric or esophageal surgery 2. Active peptic ulcer disease or symptomatic helicobacter 3. Esophageal or gastric varices or esophageal peptic stricture 4. Severe dysphagia 5. History of suspected or confirmed esophageal or gastric cancer 6. History of any other malignancy in the last 2 years 7. Pregnant women or women intending to become pregnant during the trial period 8. Uncontrolled diabetes mellitus, defined as HbA1c \> 7.5% 9. Severe cardiac conditions such as cardiac arrhythmia or ischemia or cardiac pacemaker / defibrillator 10. Having any implanted electrical device (e.g. sacral nerve stimulation, brain stimulator, others) 11. Known allergy to the device's adhesives/patches 12. Severe pulmonary diseases 13. History of significant multisystem diseases (e.g. kidney failure, liver failure) 14. Known autoimmune or a connective tissue disorder (e.g. scleroderma, CREST-syndrome, Sjogren's Syndrome), requiring therapy in the preceding 2 years 15. History of Barrett's esophagus 16. Para-esophageal hiatal hernia 17. Known history of sliding hiatal hernia ≥4 cm in the last 3 years 18. Known history of erosive esophagitis Grade C or D (LA classification) in the past 5 years 19. Obesity, defined as BMI\>32 20. History of gastroparesis 21. History of fibromyalgia, epilepsy, endometriosis 22. Umbilical hernia \>3cm 23. Past usage experience with the study device 24. Those currently enrolled in any other interventional clinical study 25. Inability to sign the informed consent 26. Inability to understand and fill the reports and questionnaires included in the study 27. Inability to follow the study requisites 28. Other medical conditions/medications that would interfere with subject safety or data collection in the opinion of the PI

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GERD (gastroesophageal reflux disease) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Division of Gastroenterology & Hepatology Feinberg School of Medicine Northwestern University

    NOT_YET_RECRUITING

    Chicago, Illinois, 60611-2927, United States

  • Gastroenterology department, Emek medical center (EMC)

    RECRUITING

    Afula, Israel

  • Gastroenterology department, Rabin medical center (RMC)

    RECRUITING

    Petah Tikva, Israel

  • Gastroenterology department, Rambam Health Care Campus

    RECRUITING

    Haifa, Israel

  • Gastroenterology department, Tel Aviv Sourasky Medical Center (Ichilov)

    RECRUITING

    Tel Aviv, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.